T. Rowe Price Investment Management, Inc. Macrogenics Inc Call Options Transaction History
T. Rowe Price Investment Management, Inc.
- $163 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding MGNX
# of Institutions
170Shares Held
62.5MCall Options Held
819KPut Options Held
79.4K-
Bellevue Group Ag Kuesnacht, V89.97MShares$41.9 Million2.3% of portfolio
-
Avoro Capital Advisors LLC New York, NY6.15MShares$25.8 Million1.09% of portfolio
-
Black Rock Inc. New York, NY5.7MShares$23.9 Million0.0% of portfolio
-
State Street Corp Boston, MA4.39MShares$18.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.68MShares$15.4 Million0.0% of portfolio
About MACROGENICS INC
- Ticker MGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,458,800
- Market Cap $258M
- Description
- MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...